$BCLI
Brainstorm Cell Therapeutics Inc Stock $bcli

$bcli Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000114420415030742 Filed on May 14, 2015

Income Statement

Concept	2015 Q2	2015 Q1	2014 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$990.0K	$960.0K	$1.030M
YoY Change	135.71%	174.29%	87.27%
% of Gross Profit
Research & Development	$1.375M	$1.245M	$1.640M
YoY Change	56.78%	83.09%	92.94%
% of Gross Profit
Depreciation & Amortization	$30.00K	$20.00K	$30.00K
YoY Change	50.0%	-33.33%	50.0%
% of Gross Profit
Operating Expenses	$1.375M	$2.205M	$2.670M
YoY Change	6.26%	113.87%	90.71%
Operating Profit	-$2.363M	-$2.205M
YoY Change	82.61%	4.45%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$100.0K	-$30.00K	-$60.00K
YoY Change	-114.49%	-97.22%	-135.29%
Pretax Income	-$2.270M	-$2.240M	-$2.730M
YoY Change	14.65%	6.16%	120.16%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.265M	-$2.236M	-$2.730M
YoY Change	14.16%	5.92%	123.77%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$123.0K	-$123.6K	-$178.7K
COMMON SHARES
Basic Shares Outstanding	18.48M shares	18.39M shares	15.28M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q2	2015 Q1	2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$19.70M	$21.35M	$8.540M
YoY Change	73.87%	604.62%	144.0%
Cash & Equivalents	$1.301M	$3.494M	$4.251M
Short-Term Investments	$18.39M	$17.86M	$4.290M
Other Short-Term Assets	$110.0K	$40.00K	$30.00K
YoY Change	120.0%	33.33%	0.0%
Inventory
Prepaid Expenses		$36.00K	$52.00K
Receivables	$250.0K	$690.0K	$1.010M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$20.06M	$22.08M	$9.598M
YoY Change	64.33%	473.01%	115.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$282.0K	$290.0K	$313.0K
YoY Change	-6.62%	-11.31%	21.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$20.00K	$20.00K	$333.0K
YoY Change	0.0%	100.0%	1565.0%
Total Long-Term Assets	$303.0K	$309.0K	$313.0K
YoY Change	-4.42%	-9.12%	11.79%
TOTAL ASSETS
Total Short-Term Assets	$20.06M	$22.08M	$9.598M
Total Long-Term Assets	$303.0K	$309.0K	$313.0K
Total Assets	$20.36M	$22.39M	$9.911M
YoY Change	62.59%	433.91%	109.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$755.0K	$922.0K	$1.542M
YoY Change	-0.26%	182.82%	576.32%
Accrued Expenses	$1.505M	$1.571M	$1.347M
YoY Change	99.34%	51.93%	53.59%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.526M	$2.726M	$3.113M
YoY Change	41.75%	69.63%	133.71%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00	$120.0K
YoY Change	-100.0%	-100.0%	-81.82%
Total Long-Term Liabilities	$0.00	$0.00	$123.0K
YoY Change	-100.0%	-100.0%	-81.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.526M	$2.726M	$3.113M
Total Long-Term Liabilities	$0.00	$0.00	$123.0K
Total Liabilities	$2.526M	$2.726M	$3.236M
YoY Change	31.29%	-18.21%	62.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$66.15M	-$63.89M	-$61.65M
YoY Change			17.64%
Common Stock		$83.55M	$68.33M
YoY Change		50.87%	23.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$17.84M	$19.66M	$6.675M
YoY Change
Total Liabilities & Shareholders Equity	$20.36M	$22.39M	$9.911M
YoY Change	62.57%	433.91%	109.71%

Cashflow Statement

Concept	2015 Q2	2015 Q1	2014 Q4
OPERATING ACTIVITIES
Net Income	-$2.265M	-$2.236M	-$2.730M
YoY Change	14.16%	5.92%	123.77%
Depreciation, Depletion And Amortization	$30.00K	$20.00K	$30.00K
YoY Change	50.0%	-33.33%	50.0%
Cash From Operating Activities	-$1.650M	-$1.937M	-$2.010M
YoY Change	70.1%	395.4%	25.63%
INVESTING ACTIVITIES
Capital Expenditures	-$16.00K	$0.00	-$70.00K
YoY Change		-100.0%	600.0%
Acquisitions
YoY Change
Other Investing Activities	-$530.0K	-$13.57M	-$2.690M
YoY Change		-135800.0%	-156.16%
Cash From Investing Activities	-$550.0K	-$13.57M	-$2.760M
YoY Change	27400.0%	15858.82%	-157.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$2.348M
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.00K	$14.75M	50.00K
YoY Change	-99.89%
NET CHANGE
Cash From Operating Activities	-1.650M	-$1.937M	-2.010M
Cash From Investing Activities	-550.0K	-$13.57M	-2.760M
Cash From Financing Activities	10.00K	$14.75M	50.00K
Net Change In Cash	-2.190M	-$757.0K	-4.720M
YoY Change	-126.38%	59.03%	-247.96%
FREE CASH FLOW
Cash From Operating Activities	-$1.650M	-$1.937M	-$2.010M
Capital Expenditures	-$16.00K	$0.00	-$70.00K
Free Cash Flow	-$1.634M	-$1.937M	-$1.940M
YoY Change	68.45%	299.38%	22.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	19661000	USD
CY2014Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-15
CY2015Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	13000000	USD
CY2015Q1	bcli	Percentage Of Royalty Paymentif Licensed Product Covered By Valid Claim Or Orphan Drug Status PercentageOfRoyaltyPaymentifLicensedProductCoveredByValidClaimOrOrphanDrugStatus	0.05	pure
CY2015Q1	bcli	Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus	0.03	pure
CY2015Q1	bcli	Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus	P15Y
CY2011Q1	bcli	Amount Due To Investors AmountDueToInvestors	20000	USD
CY2014Q1	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	1080000	USD
CY2015Q1	bcli	Financial Expenses Income Net FinancialExpensesIncomeNet	31000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2111000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3494000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4251000	USD
CY2015Q1	us-gaap	Short Term Investments ShortTermInvestments	17855000	USD
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	4290000	USD
CY2015Q1	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	693000	USD
CY2014Q4	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	1005000	USD
CY2015Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	36000	USD
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	32000	USD
CY2015Q1	us-gaap	Assets Current AssetsCurrent	22078000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	9578000	USD
CY2015Q1	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	19000	USD
CY2014Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	20000	USD
CY2015Q1	us-gaap	Long Term Investments LongTermInvestments	19000	USD
CY2014Q4	us-gaap	Long Term Investments LongTermInvestments	20000	USD
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	290000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	313000	USD
CY2015Q1	us-gaap	Assets Assets	22387000	USD
CY2014Q4	us-gaap	Assets Assets	9911000	USD
CY2015Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	922000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1542000	USD
CY2015Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1571000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1347000	USD
CY2015Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	233000	USD
CY2014Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	224000	USD
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2726000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3113000	USD
CY2015Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	USD
CY2014Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	123000	USD
CY2015Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	USD
CY2014Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	123000	USD
CY2015Q1	us-gaap	Liabilities Liabilities	2726000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-61653000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	6675000	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22387000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9911000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	232000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	347000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-2111000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-2236000	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	0.18
CY2014Q4	us-gaap	Liabilities Liabilities	3236000	USD
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	13000	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	11000	USD
CY2015Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	83537000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	68317000	USD
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-63889000	USD
	invest	Investment Warrants Exercise Price InvestmentWarrantsExercisePrice	2.25
CY2009	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	74667	shares
	bcli	Stock Option Expiration Term StockOptionExpirationTerm	P10Y
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00005
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00005
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18393546	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15281497	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18393546	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15281497	shares
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	680000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1245000	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	351000	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	960000	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	1031000	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	2205000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2236000	USD
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	0.12
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11753706	shares
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18128440	shares
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	3982000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	2739000	USD
CY2013	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	197000	USD
CY2014	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	198000	USD
CY2015Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	0	USD
CY2015Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	347000	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2497000	USD
CY2013	bcli	Stock Issued During Period For Private Placement Value StockIssuedDuringPeriodForPrivatePlacementValue	250000	USD
CY2014	bcli	Stock Issued During Period For Private Placement Value StockIssuedDuringPeriodForPrivatePlacementValue	9554000	USD
CY2013	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	30000	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	8000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	30000	USD
CY2014	bcli	Stock Issued During Period Value Issued For Warrants Exchange StockIssuedDuringPeriodValueIssuedForWarrantsExchange	1633000	USD
CY2014	bcli	Adjustments To Additional Paid In Capital Warrant Redemption In Cash AdjustmentsToAdditionalPaidInCapitalWarrantRedemptionInCash	42000	USD
CY2014	bcli	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	701000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-4899000	USD
CY2013	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	674000	USD
CY2014	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1024000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	233000	USD
CY2014Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1071000	USD
CY2015Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	7000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-9246000	USD
CY2014Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	25000	USD
CY2015Q1	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	23000	USD
CY2014Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	110000	USD
CY2015Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2014Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	122000	USD
CY2015Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	347000	USD
CY2014Q1	bcli	Increase In Accounts Receivable And Prepaid Expenses IncreaseInAccountsReceivableAndPrepaidExpenses	-117000	USD
CY2015Q1	bcli	Increase In Accounts Receivable And Prepaid Expenses IncreaseInAccountsReceivableAndPrepaidExpenses	-309000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	98000	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-620000	USD
CY2014Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	177000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-391000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1937000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	94000	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2014Q1	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	0	USD
CY2015Q1	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	13565000	USD
CY2014Q1	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	-9000	USD
CY2015Q1	bcli	Investment In Lease Deposit InvestmentInLeaseDeposit	0	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-85000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13565000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2015Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	2348000	USD
CY2014Q1	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
CY2015Q1	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	-12397000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14745000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-476000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-757000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3503000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3027000	USD
CY2014Q1	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2015Q1	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	130000	USD
CY2015Q1	dei	Document Type DocumentType	10-Q
CY2015Q1	dei	Amendment Flag AmendmentFlag	false
CY2015Q1	dei	Document Period End Date DocumentPeriodEndDate	2015-03-31
CY2015Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2015Q1	dei	Entity Registrant Name EntityRegistrantName	BRAINSTORM CELL THERAPEUTICS INC.
CY2015Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001137883
CY2015Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2015Q1	dei	Trading Symbol TradingSymbol	BCLI
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18480957	shares
CY2015Q1	bcli	Exercise Of Liability Classified Warrants ExerciseOfLiabilityClassifiedWarrants	145000	USD
CY2015Q1	bcli	Exercise Of Equity Classified Warrants ExerciseOfEquityClassifiedWarrants	2333000	USD
CY2015Q1	bcli	Exercise And Reissuance Of Warrants Value ExerciseAndReissuanceOfWarrantsValue	12397000	USD

Files In Submission

Name	View Source	Status
0001144204-15-030742-index-headers.html	Edgar Link	pending
0001144204-15-030742-index.html	Edgar Link	pending
0001144204-15-030742.txt	Edgar Link	pending
0001144204-15-030742-xbrl.zip	Edgar Link	pending
bcli-20150331.xml	Edgar Link	completed
bcli-20150331.xsd	Edgar Link	pending
bcli-20150331_cal.xml	Edgar Link	unprocessable
bcli-20150331_def.xml	Edgar Link	unprocessable
bcli-20150331_lab.xml	Edgar Link	unprocessable
bcli-20150331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
image_017.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v409490_10q.htm	Edgar Link	pending
v409490_ex10-1.htm	Edgar Link	pending
v409490_ex10-2.htm	Edgar Link	pending
v409490_ex10-3.htm	Edgar Link	pending
v409490_ex10-4.htm	Edgar Link	pending
v409490_ex31-1.htm	Edgar Link	pending
v409490_ex31-2.htm	Edgar Link	pending
v409490_ex32-1.htm	Edgar Link	pending
v409490_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCLI
Brainstorm Cell Therapeutics Inc Stock $bcli

2015 Q2 Form 10-Q Financial Statement

#000114420415030742 Filed on May 14, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCLI Brainstorm Cell Therapeutics Inc Stock $bcli

2015 Q2 Form 10-Q Financial Statement

#000114420415030742 Filed on May 14, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCLI
Brainstorm Cell Therapeutics Inc Stock $bcli